Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | GCG | P01275 | 4/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | GIPR | P48546 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | HPN | P05981 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719528 | 0.94 | RCE1 (0.39) | RCE1GCGPDE7AEPHX2GLP1R | |
| SCHEMBL718728 | 0.84 | RCE1 (0.44) | RCE1GCGPDE7AGLP1RGCGR | |
| SCHEMBL720764 | 0.84 | RCE1 (0.46) | RCE1PDE7AGCGR | |
| SCHEMBL718249 | 0.83 | RCE1 (0.44) | RCE1PDE7AGCGR | |
| SCHEMBL14905728 | 0.82 | RCE1 (0.43) | RCE1GCGEPHX2GLP1RGCGR | |
| SCHEMBL14905709 | 0.81 | RCE1 (0.45) | RCE1GCGPDE7ALTA4H | |
| SCHEMBL3101390 | 0.80 | MAPK11 (0.41) | RCE1GCGEPHX2GLP1RGCGR | |
| SCHEMBL14905675 | 0.80 | RCE1 (0.46) | RCE1GCGEPHX2GLP1RGCGR | |
| SCHEMBL14905693 | 0.79 | RCE1 (0.45) | RCE1PDE7ALTA4H | |
| SCHEMBL719872 | 0.77 | PDE2A (0.42) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-102015641-A | Heterocyclic compound | TAKEDA PHARMACEUTICAL | 2011-04-13 | — | — | CN | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RCE1 2661/4885GCG 35/4885PDE7A 2449/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RCE1 2661/4885GCG 35/4885PDE7A 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.